Introduction: A variety of causes may induce sudden deafness. However, it remains challenging to determine the exact cause in a clinic. There is no standard treatment for this disease due to its unclear etiology.
Objective: The present study aims to investigate the clinical efficacy of the intratympanic injection of dexamethasone for treating sudden deafness.
Methods: A total of 154 patients with sudden deafness were retrospectively analyzed. The evaluation of sudden deafness was based on the AAO-HNS efficacy evaluative criteria. All patients were initially treated within seven days by an intravenous drip of methylprednisolone, vasodilator, and neurotrophic agents. These patients were divided into two groups: the treatment group (91 patients) and the control group (63 patients). Patients in the treatment group were given an intratympanic injection of dexamethasone, while patients in the control group were given conventional vasodilators and neurotrophic treatment.
Results: The effective rate in the treatment group was 47.25% (43/91 patients), and this was significantly higher than in the control group (14.29%, 9/63 patients). The adverse reactions in the treatment group included transient pain (7.69%, 7/91), but there was no vertigo in either group. There was one case of tympanic membrane perforation.
Conclusion: The intratympanic injection of dexamethasone is a better choice for refractory sudden deafness due to its high efficacy and fewer adverse reactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216197 | PMC |
| http://dx.doi.org/10.2147/IJGM.S304123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[ORL : what's new in 2024].
Rev Med Suisse
January 2025
Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article highlights recent advancements in otorhinolaryngology. It reviews innovations in managing sudden sensory-neural hearing loss through low-dose glucocorticoid treatments and explores pediatric audiology breakthroughs, particularly gene therapy for DFNB9 deafness. In speech pathology and oncology, a new minimally invasive robotic surgical approach enhances organ preservation for head and neck cancers.
View Article and Find Full Text PDF[Local injections of glucocorticoids at different regions in the treatment of sudden sensorineural hearing loss: a Meta-analysis].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
Department of Pathology and Pathophysiology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing210023, China.
To compare the efficacy and safety of postauricular injection (PI) and intratympanic injection (II) of glucocorticoids (GC) in the initial treatment of sudden sensorineural hearing loss (SHL). Electronic databases retrieval (PubMed, Web of Science, CNKI, VIP, WANFANG) was performed to identify all randomized controlled trials about PI and II of GC in the initial treatment of SHL between 2015 and 2024. Meta-analysis was performed on the studies met the inclusion criteria by RevMan5.
View Article and Find Full Text PDF[Application of 3D-Flair MRI and vestibular function assessment in profound sudden sensorineural hearing loss patients].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
Department of Otology Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan250022, China.
To analyse the 3D-Flair MRI manifestations of the inner ear, vestibular function status, and their correlation with hearing treatment outcomes in patients with severe sudden sensorineural hearing loss (SSNHL), and to explore potential prognostic indicators for sudden deafness. The clinical data of adult patients with unilateral profound sudden sensorineural hearing loss were retrospectively analyzed in Otorhinolaryngology Department of Shandong Provincial ENT Hospital from March 2018 to August 2020. Patients were categorized based on the results of their inner ear 3D-Flair MRI into two groups: the normal MRI group and the abnormal MRI group.
View Article and Find Full Text PDFClinical features and short-term outcomes of bilateral sudden sensorineural hearing loss: an eight-year experience at a tertiary center.
Acta Otolaryngol
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Electric Power Hospital, Beijing, China.
Background: Sudden sensorineural hearing loss (SSNHL) typically affects one ear and is often linked to various underlying causes. However, bilateral SSNHL (BSSHL), where both ears are affected, is much rarer and presents a more severe clinical challenge.
Aims/objectives: To report the clinical features and short-term outcomes of patients with BSSHL.
Neurovascular coupling dysfunction associated with inflammatory factors in sudden sensorineural hearing loss.
Neuroscience
January 2025
Department of Radiology, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China. Electronic address:
Purpose: The neuropathologic mechanisms of sudden sensorineural hearing loss (SSNHL) are unknown. The aim of this study was to investigate the alterations of neurovascular coupling (NVC) in patients with SSNHL and its association with hematologic inflammatory factors.
Methods: The amplitude of low-frequency fluctuations (ALFF), fractional amplitude of low-frequency fluctuations (fALFF), regional homogeneity (ReHo), and degree centrality (DC) were calculated in 48 patients with SSNHL and 54 age-, gender-, and education-matched healthy control (HC), and also utilized the arterial spin labeling imaging (ASL) to calculate cerebral blood flow (CBF).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!